Dublin, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Acute Coronary Syndrome: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The $1.9bn acute coronary syndrome (ACS) market will experience moderate growth over the forecast period, driven by uptake of Brilinta and Xarelto in the secondary-prevention setting.

This report addresses the following questions:

- How will the updated 2016 treatment guidelines impact the use of new antiplatelet agents Effient and Brilinta?
- How will Brilinta's label expansion impact its sales within ACS?
- How will Xarelto's expected US approval in ACS affect its patient share in comparison to generic warfarin?
- What are the most commonly prescribed therapies for ACS in the acute and secondary-prevention treatment settings?
- What are the most important factors influencing prescribing trends in ACS?

Key Topics Covered:

FORECAST: ACUTE CORONARY SYNDROME

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Angiomax (bivalirudin)
- Brilinta (ticagrelor)
- Effient (prasugrel)
- Kengreal (cangrelor)
- Plavix (clopidogrel)
- Xarelto (rivaroxaban)
- Zontivity (vorapaxar)
- Primary Research Methodology

TREATMENT: ACUTE CORONARY SYNDROME

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Prescribing Trends

EPIDEMIOLOGY: ACUTE CORONARY SYNDROME IN THE US, JAPAN, AND 5EU

- Executive Summary
- Disease Definition
- Global Variation
- Risk Factors
- Co-Morbidities
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

MARKETED DRUGS: ACUTE CORONARY SYNDROME

- Executive Summary
- Product Overview
- Product profile: Angiomax
- Product profile: Brilinta
- Product profile: Effient
- Product profile: Kengreal
- Product profile: Plavix
- Product profile: Xarelto
- Product profile: Zontivity

For more information about this report visit http://www.researchandmarkets.com/research/tqdmkb/acute_coronary

Related Topics: Cardiovascular Drugs

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716